Multivariable regression analyses demonstrated the superior improvement in CAP and FLI observed with PCSK9-i is independent of concomitant sodium-glucose co-transporter 2 inhibitor (SGLT-2i) therapy.<h4>Conclusion</h4>PCSK9i effectively reduced hepatic steatosis surrogate scores (FLI, CAP) and lipid levels (TC, LDL-C) in patients with MAFLD combined with T2DM. This evidence concerns the gene PCSK9 and type 2 diabetes mellitus.